ArticleNeuro-oncology advances
Prognostic impact of circulating vitamin D and genetic variants in the vitamin D pathway in glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitamin D (VitD) signaling is implicated in cancer and immune regulation, but its role in glioblastoma (GBM) remains unclear. We investigated the prognostic impact of VitD levels, VDR expression, and polymorphisms in VitD-related genes in GBM. Methods: Ninety GBM tumors (62 primary, 28 recurrent) were analyzed. Circulating 25-hydroxyvitamin D (25(OH)D) was measured in 54 cases; tumor VDR mRNA/protein, calcitriol, and CYP24A1/CYP27B1/CYP27A1 proteins were assessed. Whole-exome sequencing identified SNPs in the VitD-pathway genes. Associations with overall (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier and Cox models. Transcriptomic profiles were explored by GSEA. Results: Severe 25(OH)D deficiency (<10 ng/mL) was frequent (13 primary, 38.2%; 11, recurrent 55.0%). Patients with <10 ng/mL had significantly shorter OS than patients with higher levels (9 vs. 18 months; HR = 2.55, 95% CI 1.03-6.39, Conclusions: Severe VitD deficiency (<10 ng/mL) and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.